Cargando…

Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study

PURPOSE: The present study aims to evaluate whether perfusion parameters in prostate magnetic resonance imaging (MRI), ((68))Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT), prostate-specific antigen (PSA), and PSA density can be used to predi...

Descripción completa

Detalles Bibliográficos
Autores principales: Akkaya, Hüseyin, Dilek, Okan, Özdemir, Selim, Taş, Zeynel Abidin, Öztürk, İhsan Sabri, Gülek, Bozkurt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679545/
https://www.ncbi.nlm.nih.gov/pubmed/37395389
http://dx.doi.org/10.4274/dir.2023.232186
_version_ 1785150600750563328
author Akkaya, Hüseyin
Dilek, Okan
Özdemir, Selim
Taş, Zeynel Abidin
Öztürk, İhsan Sabri
Gülek, Bozkurt
author_facet Akkaya, Hüseyin
Dilek, Okan
Özdemir, Selim
Taş, Zeynel Abidin
Öztürk, İhsan Sabri
Gülek, Bozkurt
author_sort Akkaya, Hüseyin
collection PubMed
description PURPOSE: The present study aims to evaluate whether perfusion parameters in prostate magnetic resonance imaging (MRI), ((68))Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT), prostate-specific antigen (PSA), and PSA density can be used to predict the lesion grade in patients with prostate cancer (PCa). METHODS: The study included a total of 137 PCa cases in which 12-quadrant transrectal ultrasound-guided prostate biopsy (TRUSBx) was performed, the Gleason score (GS) was determined, and pre-biopsy multiparametric prostate MRI and ((68))Ga-PSMA PET/CT examinations were undertaken. The patient population was evaluated in three groups according to the GS: (1) low risk; (2) intermediate risk; (3) high risk. The PSA, PSA density, pre-TRUSBx ((68))Ga-PSMA PET/CT maximum standardized uptake value (SUV(max)), perfusion MRI parameters [maximum enhancement, maximum relative enhancement, T0 (s), time to peak (s), wash-in rate (s(-1)), and wash-out rate (s(-1))] were retrospectively evaluated. RESULTS: There was no significant difference between the three groups in relation to the PSA, PSA density, and ((68))Ga-PSMA PET/CT SUV(max) (P > 0.05). However, the values of maximum enhancement, maximum relative enhancement (%), T0 (s), time to peak (s), wash-in rate (s(-1)), and wash-out rate (s(-1)) significantly differed among the groups. A moderate positive correlation was found among the prostate volume, PSA (r = 0.490), and ((68))Ga-PSMA SUV(max) (r = 0.322) in the patients. The wash-out rate (s(-1)) and wash-in rate (s(-1)) had the best diagnostic test performance (area under the curve: 89.1% and 78.4%, respectively). CONCLUSION: No significant correlation was found between the ((68))Ga-PSMA PET/CT SUV(max) and the GS. The wash-out rate was more successful in estimating the pretreatment GS than the ((68))Ga-PSMA PET/CT SUV(max).
format Online
Article
Text
id pubmed-10679545
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-106795452023-12-05 Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study Akkaya, Hüseyin Dilek, Okan Özdemir, Selim Taş, Zeynel Abidin Öztürk, İhsan Sabri Gülek, Bozkurt Diagn Interv Radiol Abdominal Imaging - Original Article PURPOSE: The present study aims to evaluate whether perfusion parameters in prostate magnetic resonance imaging (MRI), ((68))Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT), prostate-specific antigen (PSA), and PSA density can be used to predict the lesion grade in patients with prostate cancer (PCa). METHODS: The study included a total of 137 PCa cases in which 12-quadrant transrectal ultrasound-guided prostate biopsy (TRUSBx) was performed, the Gleason score (GS) was determined, and pre-biopsy multiparametric prostate MRI and ((68))Ga-PSMA PET/CT examinations were undertaken. The patient population was evaluated in three groups according to the GS: (1) low risk; (2) intermediate risk; (3) high risk. The PSA, PSA density, pre-TRUSBx ((68))Ga-PSMA PET/CT maximum standardized uptake value (SUV(max)), perfusion MRI parameters [maximum enhancement, maximum relative enhancement, T0 (s), time to peak (s), wash-in rate (s(-1)), and wash-out rate (s(-1))] were retrospectively evaluated. RESULTS: There was no significant difference between the three groups in relation to the PSA, PSA density, and ((68))Ga-PSMA PET/CT SUV(max) (P > 0.05). However, the values of maximum enhancement, maximum relative enhancement (%), T0 (s), time to peak (s), wash-in rate (s(-1)), and wash-out rate (s(-1)) significantly differed among the groups. A moderate positive correlation was found among the prostate volume, PSA (r = 0.490), and ((68))Ga-PSMA SUV(max) (r = 0.322) in the patients. The wash-out rate (s(-1)) and wash-in rate (s(-1)) had the best diagnostic test performance (area under the curve: 89.1% and 78.4%, respectively). CONCLUSION: No significant correlation was found between the ((68))Ga-PSMA PET/CT SUV(max) and the GS. The wash-out rate was more successful in estimating the pretreatment GS than the ((68))Ga-PSMA PET/CT SUV(max). Galenos Publishing 2023-09-05 /pmc/articles/PMC10679545/ /pubmed/37395389 http://dx.doi.org/10.4274/dir.2023.232186 Text en © Copyright 2023 by Turkish Society of Radiology | Diagnostic and Interventional Radiology, published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc/4.0/Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Abdominal Imaging - Original Article
Akkaya, Hüseyin
Dilek, Okan
Özdemir, Selim
Taş, Zeynel Abidin
Öztürk, İhsan Sabri
Gülek, Bozkurt
Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
title Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
title_full Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
title_fullStr Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
title_full_unstemmed Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
title_short Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
title_sort can the gleason score be predicted in patients with prostate cancer? a dynamic contrast-enhanced mri, ((68))ga-psma pet/ct, psa, and psa-density comparison study
topic Abdominal Imaging - Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679545/
https://www.ncbi.nlm.nih.gov/pubmed/37395389
http://dx.doi.org/10.4274/dir.2023.232186
work_keys_str_mv AT akkayahuseyin canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy
AT dilekokan canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy
AT ozdemirselim canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy
AT taszeynelabidin canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy
AT ozturkihsansabri canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy
AT gulekbozkurt canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy